- Report
- March 2024
- 199 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Clinical Trials
- April 2024
- 75 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- July 2022
- 146 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- January 2022
- 200 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Drug Pipelines
- January 2019
- 40 Pages
Global
From €1448EUR$1,500USD£1,242GBP
- Report
- July 2022
- 120 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- August 2022
Global
From €763EUR$790USD£654GBP
- Report
- July 2022
- 109 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- October 2020
- 144 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- January 2021
- 141 Pages
China, Global
From €3000EUR$3,330USD£2,663GBP
Polycystic Kidney Disease (PKD) is a genetic disorder that affects the kidneys and other organs. It is characterized by the growth of numerous cysts in the kidneys, which can lead to kidney failure. Treatment for PKD includes medications to reduce the size of the cysts, slow their growth, and reduce the risk of complications.
The market for drugs to treat PKD is part of the larger market for drugs to treat liver and kidney disorders. These drugs are used to treat a variety of conditions, including PKD, chronic kidney disease, and liver cirrhosis. The market is driven by the increasing prevalence of these disorders, as well as advances in medical technology and the development of new drugs.
Companies in the PKD drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
